November 4^th, 2024 – As Transversal Therapeutics (CURA owned subsidiary company) pursues non-dilutive funding opportunities in the drug toxicology space, we are excited to announce that we have recently received the notice of allowance for our patent application titled "Durable Enzyme-Based Biosensor and Process for Drop Deposition Immobilization" in the United States.

This patent, which has already been granted in China, is a core patent for Transversal's IP portfolio, and outlines a drop-cast surface chemistry architecture by which robust and stable electrochemical sensors can be developed. The resulting lower batch-to-batch variation and greater than 18-month shelf life of electrochemical sensors employing this technology make its commercialization viable and sets it apart from its competitors.  This has profound implications for our platform across myriad applications in the drug of abuse (DoA) space and beyond and bolsters the chance of success of our applications for non-dilutive funding over the long term.  

In the past year, Transversal has applied for two National Institute on Drug Abuse (NIDA) grants to develop rapid point-of-care (PoC) sensors in the hopes of addressing deep concerns with the management of the Opioid Crisis and the treatment of Opioid Use Disorder (OUD). We believe patients and providers deserve more convenient and precise tools to combat this worsening epidemic. The news of this patent's allowance comes just in time as we prepare 2 more grant applications for submission in February of 2025.

Transversal will continue to build on this success into the new year and beyond as a core part of our platform receives key protection. More updates will follow as we begin new exciting projects in the DoA space, stay tuned!